AEterna Zentaris Inc. Stock News

AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is W

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which w

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut

Aeterna Zentaris was one of my previous winners, but a disappointing commercial launch for their flagship product, Macrilen, caused the share price to bleed for most of 2020. The company has been maki

CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev

The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) went up 237.37% over the past week. This is why it happened.

The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) is trading at over 50% pre-market as of 7:48 AM. This is why it happened.

- Company secures next step to continue to build-out pipeline of assets

- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis op

CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut

– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –

CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmace